WaferGen Q1 Revenues Rise Sharply; Company Files Prospectus for Offering by Shareholders | GenomeWeb

NEW YORK (GenomeWeb News) – WaferGen BioSystems said in a regulatory document that revenues for its first quarter more than doubled year over year.

It separately also announced a stock sale by shareholders of up to more than 112 million shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.